Skip to content

US · ACOG · BIOTECHNOLOGY

Alpha Cognition Inc (ACOG) intrinsic value and stock valuation

$9.00as of 2026-11-21 · Mkt cap 132.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alpha Cognition Inc DCF and intrinsic value

InvestorsCraft values ACOG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACOG’s statements →

Alpha Cognition Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Grapevine, TX 76051 alphacognition.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$10.2M
20182025
Net income
-$-20.67M
20182025
Free cash flow
-$-20.67M
20192025
Total equity
$62.5M+400% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$10.2M$0.00$0.00$0.00$0.00
Operating income-$-22.66M-$-11.86M-$-9.62M-$-18.09M-$-14.74M
Net income-$-20.67M-$-14.64M-$-13.77M-$-16.28M-$-24.91M
EPSd-$-1.17M-$-2.02M-$-3.84M-$-5.99M-$-11.69M
Operating cash flow-$-20.38M-$-7.76M-$-8.73M-$-12.42M-$-12.59M
Capital expenditure-$-290K-$-30K-$0.00-$-10K-$-80K
Free cash flow-$-20.67M-$-7.78M-$-8.73M-$-12.42M-$-12.67M
Total assets$79.7M$50.7M$2.45M$3.97M$16.4M
Total debt$0.00$910K$1.22M$1.63M$1.37M
Net debt-$-66.11M-$-47.63M-$-270K-$-1.17M-$-13.03M
Total equity$62.5M$41.5M-$-4.71M-$-1.77M$11.5M
Cash and short-term investments$66.1M$48.6M$1.49M$2.8M$14.4M
Income statement
20252024202320222021
Revenue$10.2M$0.00$0.00$0.00$0.00
Cost of revenue$1.92M$0.00$0.00$0.00$0.00
Gross profit$8.3M$0.00$0.00$0.00$0.00
Research and development expenses$1.87M$3.92M$5M$11.9M$10.2M
Selling, general and administrative expenses$29.1M$7.32M$4.69M$5.44M$4.31M
Other expenses$20K$620K-$-70K$810K$270K
Operating expenses$31M$11.9M$9.62M$18.1M$14.7M
Cost and expenses$32.9M$11.9M$9.62M$18.1M$14.7M
Interest income$1.9M$160K$10K$0.00$0.00
Interest expense$0.00$190K$70K$230K$670K
Depreciation and amortization$60K$80K$80K$120K$110K
Ebitda-$-22.66M-$-14.37M-$-13.62M-$-15.92M-$-24.12M
Operating income-$-22.66M-$-11.86M-$-9.62M-$-18.09M-$-14.74M
Total other income/expenses, net$1.99M-$-2.78M-$-4.15M$1.82M-$-10.17M
Income before tax-$-20.67M-$-14.64M-$-13.77M-$-16.28M-$-24.91M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.67M-$-14.64M-$-13.77M-$-16.28M-$-24.91M
Weighted average shares outstanding$17.7M$7.25M$3.59M$2.72M$2.13M
Weighted average diluted shares outstanding$17.7M$7.25M$3.59M$2.72M$2.13M
Balance sheet
20252024202320222021
Cash and short-term investments$66.1M$48.6M$1.49M$2.8M$14.4M
Net receivables$4.24M$250K$60K$0.00$0.00
Inventory$5.12M$620K$0.00$0.00$0.00
Total current assets$79M$50.3M$1.92M$3.13M$15.5M
Property, plant and equipment, net$330K$30K$0.00$10K$20K
Goodwill and intangible assets$390K$410K$530K$830K$890K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$720K$490K$530K$830K$900K
Total assets$79.7M$50.7M$2.45M$3.97M$16.4M
Accounts payable$3.07M$870K$0.00$2.71M$580K
Short-term debt$0.00$910K$1.22M$1.63M$1.37M
Deferred revenue$150K$0.00$10K$0.00$0.00
Total current liabilities$9.13M$3.35M$2.62M$5.45M$2.3M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$40K$0.00$0.00$0.00$0.00
Total non-current liabilities$8.07M$5.92M$4.54M$290K$2.61M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$17.2M$9.27M$7.16M$5.74M$4.91M
Common stock$133.9M$99.1M$50.4M$54.1M$51M
Retained earnings-$-97.11M-$-76.29M-$-63.35M-$-67.16M-$-48.47M
Accumulated other comprehensive income (loss)-$-100K-$-100K$8.29M$11.3M$8.99M
Total equity$62.5M$41.5M-$-4.71M-$-1.77M$11.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$910K$1.22M$1.63M$1.37M
Net debt-$-66.11M-$-47.63M-$-270K-$-1.17M-$-13.03M
Cash flow statement
20252024202320222021
Net income-$-20.67M-$-14.64M-$-13.77M-$-16.28M-$-24.91M
Depreciation and amortization$60K$80K$80K$120K$110K
Stock-based compensation$4.92M$980K$2.37M$2.29M$2.29M
Change in working capital-$-4.62M-$-240K-$-1.56M$3.67M-$-370K
Accounts receivable-$-4.24M$0.00$0.00$0.00$0.00
Inventory-$-4.51M-$-620K$0.00$0.00$0.00
Accounts payable$6.52M$1.05M$0.00$2.84M$310K
Net cash provided by operating activities-$-20.38M-$-7.76M-$-8.73M-$-12.42M-$-12.59M
Investments in property, plant and equipment-$-290K-$-30K$0.00-$-10K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$670K
Net cash used for investing activities-$-290K-$-30K$0.00-$-10K$590K
Common stock issued$41.6M$56.5M$9.22M$0.00$17.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$38.2M$54.9M$8.16M$30K$19M
Net change in cash$17.5M$47.1M-$-590K-$-12.39M$6.85M
Cash at end of period$66.1M$48.6M$1.49M$2.8M$14.4M
Operating cash flow-$-20.38M-$-7.76M-$-8.73M-$-12.42M-$-12.59M
Capital expenditure-$-290K-$-30K-$0.00-$-10K-$-80K
Free cash flow-$-20.67M-$-7.78M-$-8.73M-$-12.42M-$-12.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alpha Cognition Inc

        Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

        CEO
        Michael E. McFadden
        Employees
        71
        Beta
        2.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Alpha Cognition Inc (ACOG)?

        InvestorsCraft does not currently publish an intrinsic value for ACOG. How the IC value is calculated.

        Is ACOG undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACOG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.